|
gptkbp:instanceOf
|
gptkb:drug
gptkb:biguanide
|
|
gptkbp:approvedInUS
|
1994
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50–60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:category
|
gptkb:antidiabetic_medication
|
|
gptkbp:chemicalFormula
|
C4H11N5
|
|
gptkbp:contraindication
|
liver failure
severe kidney disease
|
|
gptkbp:discoveredBy
|
gptkb:James_Bell
gptkb:Emile_Werner
|
|
gptkbp:discoveredIn
|
1922
|
|
gptkbp:drugClass
|
antihyperglycemic agent
|
|
gptkbp:effectOnWeight
|
weight neutral or modest loss
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:firstSynthesized
|
1922
|
|
gptkbp:form
|
gptkb:tablet
oral solution
extended-release tablet
|
|
gptkbp:foundIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
1957
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
|
|
gptkbp:meltingPoint
|
223–226 °C
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164 g/mol
|
|
gptkbp:origin
|
derived from Galega officinalis
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:prescribes
|
adults
children over 10 years
|
|
gptkbp:prescriptionStatus
|
Rx only
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:riskOfHypoglycemia
|
low
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis
|
|
gptkbp:usedFor
|
gptkb:polycystic_ovary_syndrome
gptkb:type_2_diabetes
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
true
|
|
gptkbp:bfsParent
|
gptkb:DB00740
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Metformin
|